FGFR2 and gastrointestinal stromal tumor: In particular, FGF2 was found to be overexpressed in imatinib-resistant GIST cells as well as in tumor samples from imatinib-resistant GIST patients, where also a genomic gain of FGFR2 was identified [7,11].